Competitor Analysis - p38 MAPK Inhibitors 2010

  • ID: 1417854
  • Report
  • 21 Pages
  • La Merie Publishing
1 of 3
p38 MAP Kinase (MAPK) Inhibitors:

The present Competitive Intelligence Report about p38 MAPK inhibitors used to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, COPD or pain, respectively, provides a competitor evaluation in the field of R&D projects with p38 MAPK inhibitors as of November 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The next generation of p38 mitogen-activated protein kinase (MAPK) inhibitors has reached clinical proof-of-concept studies in phase II in a broad range of indications. While the previous generation of p38 MAPK inhibitors suffered from side effects such as liver transaminase elevations, the newer inhibitors are more selective at targeting p38 and include non-ATP competitive inhibitors directed against the conformation epitope. The p38 MAPK covers a central role in the regulation of interleukin-1 beta (IL-1beta) and TNF-alpha signaling. Thus, inhibition of p38 MAPK would be expected to decrease the production of these cytokines.

About ten p38 MAPK inhibitors are in clinical phase I and II studies, with the first agent being administered by inhalation for respiratory diseases. The anti-inflammatory properties of p38 MAPK inhibitors are being evaluated in phase II clinical studies in psoriasis, patients at risk for cardiovascular disease/atherosclerosis, rheumatoid arthritis, chronic obstructive pulmonary disease (COPD)/asthma and acute lung injuries. Further trials are assessing the value of p38 MAPK inhibition to treat pain.

The report includes a compilation of current active projects in research and development of p38 MAPK inhibitors. In addition, the report lists company-specific R&D pipelines of p38 MAPK inhibitors. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,

- Target / Mechanism of Action,

- Class of Compound,

- Company,

- Product Category/Therapeutic Area,

- Indication,

- R&D Stage and

- additional comments with a hyperlink leading to the source of information.


- p38 MAPK Inhibitors

- p38 alpha MAPK Inhibitors
Note: Product cover images may vary from those shown
2 of 3
1. p38 MAPK Inhibitors

- p38 MAPK Inhibitors
- p38 alpha MAPK Inhibitors
- Multi-Kinase Inhibitors

2. Corporate p38 MAPK Inhibitors R&D Pipelines

- Almirall
- Amgen
- Ansaris
- Array BioPharma
- Bayer Schering Pharma
- Bristol-Myers Squibb (BMS)
- c-a-i-r Biosciences
- Cytokine Pharmasciences
- Genoma Espana
- GlaxoSmithKline (GSK)
- Inovio
- Merck & Co.
- Numerate Inc
- Palau Pharma
- Pfizer
- Pinnacle
- Xcovery
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown